Process development in biotech is the work of designing, optimizing, and scaling the step-by-step methods used to manufacture biological products like antibodies, vaccines, and cell therapies. It bridges the gap between a molecule that works in a lab and one that can be reliably produced at commercial scale, at the right purity, and at a cost that makes it viable. Every biologic drug on the market went through process development before a single commercial dose was made.
The discipline pulls from biology, chemistry, and engineering. Process development scientists manipulate cells and production conditions to maximize the yield of a target product, then build purification workflows to isolate it from everything else in the mixture. They also ensure the entire workflow can scale from a benchtop flask to a manufacturing facility, all while meeting strict regulatory requirements.
Upstream Process Development
Upstream development covers everything that happens before purification: selecting the right cell line, choosing the growth media, and dialing in the conditions inside a bioreactor. For monoclonal antibodies, which represent a large share of biotech products, the workhorse is typically a Chinese hamster ovary (CHO) cell line engineered to produce the target protein.
Cell line development starts with inserting the gene for the desired protein into host cells, then screening hundreds or thousands of clones to find the one that produces the most product with the best quality profile. That winning clone becomes the basis for a master cell bank, a frozen inventory of cells that serves as the starting material for every future manufacturing run.
Once the cell line is locked, scientists optimize the culture process. This means testing different combinations of seed media, basal media, and feed media (all chemically defined mixtures that supply nutrients to the cells), then running experiments in small-scale bioreactors to find the best settings for temperature, pH, dissolved oxygen, feeding schedule, and culture duration. A typical fed-batch production run might hold cells at 36.5°C with daily feeding for 14 days. Parameters like agitation speed and air flow rates also need tuning, because they affect how well oxygen and nutrients reach the cells without causing physical damage.
Process development teams use structured experimental approaches, often called Design of Experiments (DoE), to test multiple variables simultaneously rather than changing one at a time. They also perform risk assessments to rank which parameters pose the highest threat to product quality. Cell age, culture duration, pH, and temperature commonly land in the high-risk category, while initial cell density and feed volume are often rated as medium risk.
Downstream Process Development
Downstream development is the purification side. After cells have spent their time producing the target protein, the mixture in the bioreactor contains the product along with host cell proteins, DNA, cell debris, and various unwanted variants of the product itself. The job of downstream processing is to isolate the target molecule to extremely high purity.
For antibodies, the first major step after harvesting the cells is typically protein A chromatography, a technique that uses a column packed with material that selectively binds antibodies while letting most contaminants flow through. This single step provides a dramatic initial purification.
What follows is a series of polishing steps. These usually include two different types of chromatography chosen to target different classes of impurities. Ion-exchange chromatography separates molecules by electrical charge, hydrophobic interaction chromatography sorts them by how water-repellent their surfaces are, and size-exclusion chromatography separates by molecular size (typically reserved for final stages). A general rule: remove the most abundant impurities first. Virus inactivation and removal steps are also built into the sequence, since the product is derived from living cells. At the end, the purified protein goes through a buffer exchange step that stabilizes it and prepares it for its final formulation.
The Scale-Up Problem
A process that works perfectly in a 5-liter benchtop bioreactor does not automatically work in a 2,000- or 20,000-liter commercial vessel. Scale-up is one of the most technically demanding phases of process development, because the physics inside the reactor change as the volume grows. Mixing that takes seconds in a small vessel can take minutes in a large one. Gas bubbles behave differently. Heat distribution shifts.
These differences have real consequences. When Human Genome Sciences started up a 20,000-liter facility, they observed lower cell growth and lower product output than they had seen at pilot scale. Computational fluid dynamic modeling, essentially a simulation of liquid movement inside the vessel, revealed that mixing time was the culprit. In another case, researchers found that increased gas sparging (bubbling air through the culture to supply oxygen) caused significant cell damage at the sparger site in 600-liter cultures, leading to poor cell survival and low antibody yield.
To anticipate these problems, teams build scale-down models: small bioreactors deliberately configured to mimic the imperfect conditions of large-scale equipment. By testing in these models before committing to expensive large-scale runs, they can identify and solve problems early.
Quality by Design
Modern process development follows a framework called Quality by Design (QbD), a systematic approach where quality is built into the process from the start rather than tested for at the end. QbD begins by defining the critical quality attributes of the final product: the specific characteristics (purity, potency, stability) that determine whether it is safe and effective.
From there, teams work backward to identify which process parameters and raw material properties affect those quality attributes. Using risk assessment tools like Failure Mode and Effects Analysis (FMEA) and structured experiments, they map out a “design space,” a defined range of operating conditions proven to consistently produce acceptable product. If a bioreactor can run between 36°C and 37°C and between pH 6.8 and 7.2 while still meeting all quality targets, that window is part of the design space. The practical benefit is regulatory flexibility: changes made within an approved design space do not require re-approval from regulators, which gives manufacturers room to optimize without triggering lengthy review cycles.
Regulatory Expectations
Process development teams must document their work thoroughly to satisfy regulatory agencies. The FDA evaluates biologics through a Chemistry, Manufacturing, and Controls (CMC) framework that covers every aspect of how a product is made, tested, and controlled. International guidelines from the ICH, particularly Q8 (pharmaceutical development), Q11 (drug substance manufacturing), and Q9 (quality risk management), lay out the expectations for how process knowledge should be generated and presented.
A separate guideline on process validation requires manufacturers to demonstrate, with data, that their process consistently produces product meeting its quality specifications. This is not a one-time event. It spans the entire product lifecycle, from initial development through ongoing commercial production.
Single-Use vs. Stainless Steel Equipment
One of the bigger practical decisions in process development is whether to use traditional stainless steel bioreactors or single-use (disposable) systems. Stainless steel equipment is durable and well-understood, but it requires extensive cleaning and sterilization between batches. Validated clean-in-place and sterilization-in-place procedures consume significant water, personnel time, and facility space. Because each piece of equipment must be opened for cleaning, facilities need separate rooms for individual unit operations, which slows down staff movement and introduces workflow inefficiencies.
Single-use systems replace the product-contact surfaces with pre-sterilized disposable components. They can be assembled and disassembled quickly, eliminating the downtime for cleaning and sterilization validation. This translates to faster production cycles and easier customization of reactor size. The trade-off is that disposable components add ongoing material costs and create plastic waste, and the largest available single-use bioreactors are still smaller than the biggest stainless steel vessels.
Batch vs. Continuous Manufacturing
Traditional biotech manufacturing runs in batches: a defined quantity of product is made, purified, and released before the next batch starts. Continuous manufacturing, where material flows through the production system without stopping, has gained significant interest because it can reduce facility size and improve efficiency. Estimates suggest that end-to-end continuous bioprocessing could cut the cost of goods by roughly 30% while shrinking the physical footprint of a manufacturing facility.
Adoption is still in relatively early stages for biologics, though it is further along for small-molecule pharmaceuticals. Many companies are investing in hybrid approaches, linking some continuous unit operations together while keeping others as batch steps, rather than converting entire processes at once. The technical and business drivers for continuous processing, primarily safety improvements and greater manufacturing flexibility, have remained consistent even as the technology evolves.
Why It Matters Economically
Process development is one of the highest-leverage activities in biotech manufacturing. A modest improvement in cell culture titer (the concentration of product in the bioreactor) or a streamlined purification sequence can translate into millions of dollars in savings at commercial scale. The cost of goods for biologics remains significantly higher than for traditional small-molecule drugs, which makes process optimization a continuous priority rather than a one-time project. Techniques like process intensification, which aims to get more product from smaller equipment in less time, represent the current frontier of cost reduction in the industry.